This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Recombinant Factor VIIa (NovoSeven) on Restoring Coagulation Activation

This study has been completed.
Sponsor:
Information provided by:
Medical University of Vienna
ClinicalTrials.gov Identifier:
NCT00375323
First received: September 11, 2006
Last updated: April 19, 2007
Last verified: April 2007
September 11, 2006
April 19, 2007
Not Provided
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00375323 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Recombinant Factor VIIa (NovoSeven) on Restoring Coagulation Activation
Effects of Recombinant Factor VIIa (NovoSeven) on Restoring Coagulation Activation in Patients With Hemophilia A and Antibodies to Factor VIII
The purpose of the study is to compare the effects of recombinant factor VIIa (NovoSeven) on restoring coagulation activation between patients with hemophilia A and antibodies to factor VIII and normal subjects (controls) by use of an in vivo method.
Not Provided
Interventional
Phase 3
Allocation: Non-Randomized
Intervention Model: Factorial Assignment
Masking: None (Open Label)
Hemophilia A
Drug: NovoSeven
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
Not Provided
Not Provided

Inclusion Criteria:

  • Adult patients with hemophilia A and current antibodies to factor VIII -

Exclusion Criteria:

  • Life-threatening hemorrhage
  • Severe liver failure
  • Any other severe co-morbidity (including diabetes mellitus, renal failure, cancer, septicemia, disseminated intravascular coagulation, crush injury)
  • Exposure to other haemostatic drugs during the previous 7 days
  • Hypersensitivity to hamster, mouse or bovine proteins
  • Known or suspected allergy to NovoSeven or any of its components
Sexes Eligible for Study: Male
18 Years and older   (Adult, Senior)
Not Provided
Contact information is only displayed when the study is recruiting subjects
Austria
 
 
NCT00375323
NovoSeven 1
Not Provided
Not Provided
Not Provided
Not Provided
Medical University of Vienna
Not Provided
Principal Investigator: Sabine Eichinger, MD Medical University of Vienna
Medical University of Vienna
April 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP